SAN DIEGO, April 22 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq:OPTR - News) announced that data from the second fidaxomicin Phase 3 clinical study will be presented in an oral presentation at Digestive Disease Week (DDW) 2010 in New Orleans.
